Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Letermovir has shown effectiveness in preventing cytomegalovirus (CMV) infections in hematopoietic stem cell transplant recipients, while Maribavir is effective in treating refractory or resistant CMV infections, particularly in adolescent transplant recipients. Other molecules like brincidofovir, cyclopropavir, and immunomodulating molecules (e.g., leflunomide, everolimus) demonstrate potential against HCMV, though with varying levels of clinical support.
• Anti-CMV immunoglobulins have been highlighted as effective in managing congenital CMV infections and as part of combination therapies in heart transplant patients to combat CMV.
• The safety profile of current antiviral therapies, including letermovir and maribavir, is complicated by issues of toxicity and resistance; however, both letermovir and maribavir target different mechanisms, potentially mitigating toxicity concerns.
• Natural molecules and immunomodulating therapies, while generally indicating a potentially favorable safety profile, lack extensive clinical studies to firmly establish their safety, and no specific safety concerns were identified for these newer antiviral agents.